Tobam Hutchmed (China) LTD Transaction History

Tobam

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 12, 2020	SELL	$25.8 - $34.61 $1.21 Million - $1.63 Million	-46,979 Closed	0 $0
Q2 2020 Aug 17, 2020	SELL	$17.65 - $28.05 $48,502 - $77,081	-2,748 Reduced 5.53%	46,979 $1.3 Million
Q1 2020 May 07, 2020	BUY	$15.19 - $29.51 $155,317 - $301,739	10,225 Added 25.88%	49,727 $888,000
Q4 2019 Feb 10, 2020	SELL	$17.17 - $25.95 $126,216 - $190,758	-7,351 Reduced 15.69%	39,502 $990,000
Q3 2019 Nov 12, 2019	BUY	$17.84 - $22.69 $244,978 - $311,579	13,732 Added 41.46%	46,853 $836,000
Q2 2019 Aug 13, 2019	SELL	$22.0 - $31.78 $171,160 - $247,248	-7,780 Reduced 19.02%	33,121 $729,000
Q1 2019 May 15, 2019	BUY	$21.27 - $30.58 $351,295 - $505,059	16,516 Added 67.73%	40,901 $1.25 Million
Q4 2018 Feb 11, 2019	BUY	$23.09 - $37.69 $563,049 - $919,070	24,385 New	24,385 $563,000

8.25M

3.8K

2.4K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $3.11B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Tobam, based on Form 13F filings with the SEC.

Stay updated on Tobam with notifications on news.